FDA
-
-
-
-
-
-
-
Celcuity (CELC) Granted FDA Breakthrough Therapy Designation for Gedatolisib
-
-
-
-
-
-
-
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symp
-
-
-
-
-
-
-
Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
-
-
-
-
-
-
-
Celcuity (CELC) Announces Worldwide Licensing Agreement with Pfizer (PFE) to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
-
-
-
-
-
-
-
Celcuity Reports First Quarter 2020 Financial Results and Recent Business Highlights
-
-
-
251,368 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All